Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with ...

Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...

Based on phase 1 safety data, the FDA has removed the Limitations of Use for Yescarta in patients with relapsed or refractory primary CNS lymphoma. The Food and Drug Administration (FDA) has approved ...

In our experience, patients' histories often note a neurologic prodrome years before PCNSL. These lingering illnesses, suggestive of multiple sclerosis or vitritis, might reflect polyclonal lymphoid ...

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...

The risk for central nervous system (CNS) involvement is small in cases of diffuse large B-cell lymphoma (DLBCL) because only about 5% of patients develop it. But certain high-risk patients are even ...

We appreciate the kind words from Cohen 1 regarding the impact of our study but disagree with his recommendation in regard to methotrexate (MTX) dosing. We harbor reservations about ultra-high doses ...

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

Raphael announced this Wednesday his return to musical activity starting on June 15, four months after being hospitalized due to a brain lymphoma. Raphael announced this Wednesday his return to normal ...

Integrating Evidence-Based Medicine for Treatment of Spinal Metastases Into a Decision Framework: Neurologic, Oncologic, Mechanicals Stability, and Systemic Disease Primary CNS lymphoma (PCNSL) is a ...

BOSTON — Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous ...